Search research articles
Contact Us
Filters
Showing results (81-90 of 127) with videos related to
Page
of 13
Sort By:
JAMA Oncology
|
June 18, 2026
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis
Jaromir Tomasik, Tobias Tix, Mohammad Alhomoud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2016
Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation
Maximilian Merz, Lina Jansen, Felipe A Castro, et al.
Blood
|
July 27, 2016
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K Martin Kortüm, Elias K Mai, Nur H Hanafiah, et al.
Blood Advances
|
January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
Maximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Blood Cancer Journal
|
January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Katharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Blood Cancer Journal
|
August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
Maximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Nature Medicine
|
February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody
Till Braun, Michael Rade, Maximilian Merz, et al.
Bone Marrow Transplantation
|
June 3, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells
Simon M Krauß, Konstantin Weibl, Enrica Bach, et al.
Blood Advances
|
July 22, 2022
Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
Maximilian Merz, Qiang Hu, Almuth Maria Anni Merz, et al.
Haematologica
|
August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
Maximilian Merz, Hans Salwender, Mathias Haenel, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 127) with videos related to
Sort By:
Page
of 13
JAMA Oncology
|
June 18, 2026
Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis
Jaromir Tomasik, Tobias Tix, Mohammad Alhomoud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 18, 2016
Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation
Maximilian Merz, Lina Jansen, Felipe A Castro, et al.
Blood
|
July 27, 2016
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K Martin Kortüm, Elias K Mai, Nur H Hanafiah, et al.
Blood Advances
|
January 19, 2018
Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma
Maximilian Merz, Anna Jauch, Thomas Hielscher, et al.
Blood Cancer Journal
|
January 31, 2019
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Katharina Kriegsmann, Marc-Andrea Baertsch, Mohamed H S Awwad, et al.
Blood Cancer Journal
|
August 29, 2019
Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
Maximilian Merz, Thomas Hielscher, Elias Karl Mai, et al.
Nature Medicine
|
February 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody
Till Braun, Michael Rade, Maximilian Merz, et al.
Bone Marrow Transplantation
|
June 3, 2026
Clonal Hematopoiesis does not influence manufacturing of Chimeric Antigen Receptor (CAR) T-Cells
Simon M Krauß, Konstantin Weibl, Enrica Bach, et al.
Blood Advances
|
July 22, 2022
Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma
Maximilian Merz, Qiang Hu, Almuth Maria Anni Merz, et al.
Haematologica
|
August 20, 2016
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
Maximilian Merz, Hans Salwender, Mathias Haenel, et al.
Page
of 13